Sarepta Therapeutics (SRPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 330,959 | -713,410 | -430,563 | -250,616 | -447,508 |
| Depreciation Amortization | 10,064 | 39,230 | 34,357 | 17,040 | 8,066 |
| Accounts receivable | 3,416 | 203,755 | 206,249 | 74,693 | -57,383 |
| Accounts payable and accrued liabilities | -210,465 | N/A | N/A | N/A | -58,337 |
| Other Working Capital | -586,251 | 78,038 | -261,471 | -232,243 | -281,777 |
| Other Operating Activity | 249,594 | 186,908 | 114,743 | 69,026 | 253,502 |
| Operating Cash Flow | $-202,683 | $-205,479 | $-336,685 | $-322,100 | $-583,437 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -131,309 | 251,213 | 151,277 | 64,726 | -3,900 |
| PPE Investments | -2,081 | -101,972 | -98,381 | -75,447 | -43,651 |
| Purchase Of Investment | N/A | -245,819 | -245,819 | -245,819 | -241,388 |
| Sale Of Investment | N/A | 174,095 | 174,095 | N/A | N/A |
| Purchase Sale Intangibles | -1,000 | -7,876 | -7,738 | -2,426 | -2,238 |
| Other Investing Activity | -1,000 | -7,876 | -7,738 | -2,426 | -2,238 |
| Investing Cash Flow | $-134,390 | $69,641 | $-26,566 | $-258,966 | $-291,177 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 250,000 | N/A | N/A | N/A | N/A |
| Debt Repayment | -250,000 | -162,588 | -127,455 | -3,514 | N/A |
| Common Stock Issued | 241 | 38,703 | 36,119 | 17,181 | 15,681 |
| Common Stock Repurchased | N/A | -25,013 | -25,013 | -25,013 | N/A |
| Other Financing Activity | 0 | -19,446 | -12,787 | 0 | -3,210 |
| Financing Cash Flow | $241 | $-168,344 | $-129,136 | $-11,346 | $12,471 |
| Beginning Cash Position | 814,407 | 1,118,589 | 1,118,589 | 1,118,589 | 1,118,589 |
| End Cash Position | 477,575 | 814,407 | 626,202 | 526,177 | 256,446 |
| Net Cash Flow | $-336,832 | $-304,182 | $-492,387 | $-592,412 | $-862,143 |
| Free Cash Flow | |||||
| Operating Cash Flow | -202,683 | -205,479 | -336,685 | -322,100 | -583,437 |
| Capital Expenditure | -2,081 | -101,972 | -98,381 | -75,447 | -43,651 |
| Free Cash Flow | -204,764 | -307,451 | -435,066 | -397,547 | -627,088 |